Damian Brzyski earns distinguished paper award

The Eastern North American Region (ENAR) of the International Biometric Society awarded Damian Brzyski with the Distinguished Student Paper Award for his work on group SLOPE which he performed within the IDeAl project. Brzyski’s paper, entitled “Group SLOPE as Method for SNPs Selection with the False Discovery Rate Control,” is focused on a new method for identifying groups of variables in a linear regression model that have an impact on the considered response.

This week: Joint Meeting at EMA

The final stages of the projects IDeAl, InSPiRe and asterix conclude with the joint workshop Seventh Framework Programme (FP7) small-population research methods projects and regulatory application hosted by the European Medicines Agency in London. During the workshop, the three projects will have the opportunity to intertwine their research in various in-depth workshops, unify their great thinkers, and reach beyond what has been accomplished so far. The hands-on discussions will provide international representatives of patient organisations, pharmaceutical industry, academic statisticians and clinical trial methodologists, clinical researchers, pharmaceutical industry and regulators with the latest recommendations for small population group trials. As a special highlight, the meeting will be broadcasted on the EMA website and, thus, reach stakeholders from all over the world.

Malta 2017: MMA-EURORDIS-COMP-IMI Conference

Ralf-Dieter Hilgers is representing IDeAl, and disseminating the IDeAl results at the MMA-EURORDIS-COMP-IMI Conference in Malta this week. As an invited speaker, he seized the chance to present “Innovative statistical design methodologies for clinical trials in small populations focussing on rare diseases“.  This conference, organized during the Maltese Presidency aims at discussing the development of medicinal products for rare diseases. It brings together the European Organisation for Rare Diseases (EURORDIS), EU Health Ministers, experts from the Committee of Orphan Medicinal Products (COMP) and the members of the Innovative Medicines Initiative (IMI), and provides an IDeAl forum for disseminating our results to the regulators of the day.

Joint Dissemination Workshop at EMA

Three projects, Asterix, IDeAl and InSPiRe, have been funded by the EU within the Seventh Framework Programme to develop new methodology on design and analysis of small population clinical trials since 2013. A joint dissemination workshop will be held at the European Medicines Agency on 29 & 30 March 2017.

The aim of the workshop is to translate and promote novel methodologies of all three EU FP7 funded projects into tangible recommendations. This research should advance clinical research and the development of new treatments in small populations, such as in rare diseases, children or targeted therapies for personalized medicine. The results and recommendations for applications will be discussed with international representatives of patient organisations, academic statisticians, clinical trial methodologists, clinical researchers, pharmaceutical industry, HTAs and regulators.

For more details on the meeting and the agenda, visit the EMA website. To register, please contact Isabel Perez.

Please note that the meeting shall be broadcasted online via the EMA webpage (tbc).

It would be great to welcome you at the meeting!

Rare Disease Day 2017

Under the slogan “With research, possibilities are limitless”, todays Rare Disease Day 2017 is focussusing on the theme research. As the Orphanet Journal of Rare Diseases states it, continual research is necessary in order to unlock the mysteries often presented by rare diseases. The IDeAl consortium is proud to support this process with the latest advances in statistical methodology. We are on an IDeAl way!